Welcome to our dedicated page for Neuronetics SEC filings (Ticker: STIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neuronetics, Inc. filings document the public reporting record for a Nasdaq-listed medical technology and healthcare company with common stock traded under STIM. Recent Form 8-K reports furnish operating results, investor presentation materials, executive appointments and retirements, compensation arrangements, restructuring charges, and material agreements tied to credit facilities and registration rights.
The company’s proxy materials describe annual meeting voting matters, director elections, auditor ratification, advisory executive compensation votes, and equity incentive plan approvals. Together with event reports, the filings disclose governance procedures, capital-structure matters, Nasdaq-listed security information, and contractual obligations associated with Neuronetics’ medical device and clinic-services operations.
Neuronetics, Inc. reported the voting results from its Annual Meeting of Stockholders. A total of 55,950,118 shares of common stock, representing approximately 80.41% of shares outstanding and eligible to vote, were present in person or by proxy, establishing a quorum.
All seven director nominees were elected to one-year terms with individual support levels ranging from about 28.5 million to 34.5 million votes. Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
On a non-binding advisory basis, stockholders approved executive compensation with 29,133,360 votes for and 11,503,294 against. They also approved the Neuronetics, Inc. 2026 Equity Incentive Plan, which received 23,802,955 votes for and 16,651,661 against, with additional abstentions and broker non-votes on both proposals.
Neuronetics, Inc. investor Jorey Chernett reports a 15.17% ownership stake in the company’s common stock. As of the close of business on May 26, 2026, he beneficially owned 10,553,988 shares, based on 69,587,840 shares outstanding as of May 1, 2026.
The filing states that these shares were purchased with personal funds for an aggregate price of approximately $20,619,936. Chernett holds sole voting and sole dispositive power over all reported shares, with no shared voting or dispositive authority. An exhibit lists individual share transactions since the prior amendment.
Neuronetics, Inc. reported that it has updated the consulting arrangement with Francis X. Brown III, who serves as its Interim Principal Financial and Accounting Officer. Mr. Brown was previously engaged under an agreement dated April 22, 2026 and began serving as Interim PAO on May 5, 2026.
Under the new Amended and Restated Consulting Agreement dated May 18, 2026, his role is clarified to include ongoing service as Interim PAO until the company hires a full-time controller and a full-time principal financial and accounting officer or another written end date is agreed. His compensation is now set at $26,000 per month, replacing the earlier $25,000 fee for his interim services.
Neuronetics, Inc. former EVP, CFO and Treasurer Steven Pfanstiel corrected a prior insider report and now shows an open‑market sale of 8,569 shares of common stock on March 19, 2026 at a weighted average price of $1.34 per share.
The footnotes explain these were non‑discretionary sales made to satisfy his tax withholding obligation upon vesting of a performance restricted stock unit award. After this transaction, he directly holds 836,643 shares of Neuronetics common stock.
Neuronetics, Inc. large shareholder Jorey Chernett bought 100,000 shares of common stock in an open-market transaction. The shares were purchased at an average price of $1.17 per share. Following this buy, Chernett directly holds 10,553,988 Neuronetics shares.
Neuronetics, Inc. disclosed an initial statement of beneficial ownership for interim principal accounting officer Francis X. Brown III. The Form 3 shows he directly holds 19,968 shares of Common Stock as of the reported date, with no buy or sell transactions indicated.
Neuronetics, Inc. large shareholder Jorey Chernett reported an open-market purchase of 475,000 shares of Common Stock. The shares were bought at a weighted average price of $1.34 per share in multiple trades. After this transaction, Chernett directly holds 10,453,988 shares of Neuronetics common stock.
The filing notes that individual trade prices on the transaction date ranged from $1.27 to $1.36 per share, and Chernett has agreed to provide full trade-level detail upon request.
Neuronetics, Inc. reports Q1 2026 results and warns of substantial doubt about its ability to continue as a going concern because it currently projects breaching a March 31, 2027 revenue covenant on its Perceptive credit facility. Q1 revenue rose to $34.5 million, up from $32.0 million, driven mainly by a 15% increase in U.S. clinic revenue to $21.5 million. Treatment session revenue declined modestly to $9.1 million, while U.S. system revenue increased to $3.2 million on 35 systems sold. Gross margin slipped to 46.9% from 49.2%, reflecting mix within clinic revenue. Net loss narrowed to $10.8 million from $12.7 million, and operating cash outflow improved to $9.4 million. As of March 31, 2026, the company held $13.2 million in cash and cash equivalents and had $65.0 million outstanding under its Perceptive Facility, maturing in July 2029. Management is pursuing operational initiatives and has an at-the-market equity program with $41.7 million of capacity remaining, but notes these do not fully mitigate the covenant risk.
Neuronetics, Inc. reported first quarter 2026 revenue of $34.5M, up 8% from the same period in 2025, driven mainly by U.S. clinic revenue growth and higher NeuroStar system sales. U.S. clinic revenue rose to $21.5M, a 15% increase, while NeuroStar system revenue grew 13% to $3.2M. Treatment session revenue declined to $9.1M from $9.6M.
Gross margin slipped to 46.9% from 49.2%, but operating expenses fell 6% to $25.1M, narrowing the net loss to $(10.8)M, or $(0.16) per share. Adjusted EBITDA improved to $(6.6)M. Cash and restricted cash totaled $19.0M at March 31, 2026, down from $34.1M at year-end, reflecting a $5.0M debt repayment and operating cash use.
The company highlighted an Optum/UnitedHealthcare policy change allowing psychiatric mental health nurse practitioners to order and administer NeuroStar TMS in 26 states and Washington, D.C., expanding access to about 34.8 million covered lives. For full year 2026, Neuronetics expects revenue of $160–$166M with gross margin between 47–49% and cash flow from operations between $(13)M and $(17)M.
Neuronetics, Inc. insider Jorey Chernett purchased 200,000 shares of Common Stock in open-market transactions. He bought 100,000 shares on April 20 and another 100,000 shares on April 21 at weighted average prices around $1.51–$1.58 per share, executed in multiple trades within stated price ranges. After these purchases, he directly holds 9,978,988 shares of Neuronetics common stock.